BetaSense

Executive Summary

BetaSense is a Berlin-based diagnostics company developing a novel protein test for the early detection of neurodegenerative diseases such as Alzheimer's and Parkinson's. Founded in 2025, the company aims to revolutionize early diagnosis, enabling prevention and effective treatment to support healthy aging and longevity. With a team of 11-50 employees, BetaSense is in the early stages of development and has not yet disclosed funding or valuation. The company's technology focuses on identifying protein biomarkers in blood or other fluids, potentially offering a simple, clear, and accurate alternative to current diagnostic methods. As a private entity, BetaSense is poised to address a significant unmet need in the aging global population, where early intervention can dramatically improve patient outcomes and reduce healthcare costs. However, given its early stage, the company faces typical risks related to technology validation, clinical trials, and market adoption. The neurodegenerative diagnostics market is competitive, but BetaSense's differentiated approach could position it as a key player if clinical results are favorable.

Upcoming Catalysts (preview)

• Q2 2026Series A Funding Announcement70% success
• Q4 2026Initial Clinical Data Readout50% success
• Q3 2026Strategic Partnership with Pharma or Diagnostic Company40% success